Lantheus Holdings, Inc. — Q1 2019 Form 10-Q
Business context and reporting period. Lantheus develops, manufactures and commercializes diagnostic medical imaging products, including DEFINITY ultrasound contrast agent and TechneLite technetium generators. This unaudited report covers the three months ended March 31, 2019, compared with Q1 2018. The company reports U.S. and International segments.
Financial performance
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| Revenue | $86.5 million | $82.6 million | +4.7% |
| Gross profit / margin | $44.1 million / 51.0% | $42.3 million / 51.2% | Profit +4.2%; margin slightly lower |
| Operating income / margin | $16.2 million / 18.7% | $15.1 million / 18.3% | +6.8% |
| Net income | $9.9 million | $8.2 million | +21.2% |
| Diluted earnings per share | $0.25 | $0.21 | +$0.04 |
| Cash from operations | $10.5 million | $(0.7) million | Improved |
| Capital expenditures | $10.6 million | $2.1 million | Higher investment |
| Cash and cash equivalents | $112.1 million | $113.4 million at Dec. 31, 2018 | Down $1.3 million |
Operating cash flow less capital expenditures was approximately negative $0.1 million in Q1 2019, compared with negative $2.8 million in Q1 2018. Management attributed the 2019 operating cash generation primarily to earnings and noncash expenses, partly offset by working-capital outflows, including payment of prior-year bonuses.
At March 31, 2019, total current assets were $195.5 million and current liabilities $42.8 million, implying working capital of $152.7 million and a current ratio of about 4.6. Debt principal outstanding was $269.5 million; the balance sheet reported $266.1 million of debt and other borrowings, net of discounts and issuance costs and including finance leases. The term debt carried a 6.2% rate, with $261.9 million of principal scheduled for 2022. The $75 million revolving facility had no balance outstanding; availability may be constrained by credit-agreement covenants.
Changes versus prior comparable period
- DEFINITY revenue rose 14.5% to $51.1 million, principally on higher U.S. volume. Management described it as the company’s fastest-growing, highest-margin commercial product.
- TechneLite revenue increased 12.9% to $24.1 million, reflecting annual pricing adjustments and volume; the prior-year comparison was affected by a temporary supplier disruption.
- Other nuclear product revenue fell 22.4% to $15.1 million, including lower Xenon volume. Rebates and allowances also increased.
- U.S. segment revenue grew 5.5% to $75.4 million; International revenue was nearly flat at $11.1 million. Operating income increased in both segments.
- Research and development expense increased 23.6% to $4.9 million, primarily from DEFINITY clinical studies and higher employee costs. Interest expense rose approximately $0.5 million, attributed to higher debt interest rates.
- The effective tax rate declined to 22.1% from 31.6%, primarily due to increased tax benefits from stock-compensation deductions. Other income included $0.8 million of tax indemnification income.
Outlook, risks and contingencies
- No specific consolidated revenue or earnings guidance was provided. Management expects DEFINITY to continue growing and represent a larger share of product mix in 2019, and stated that available cash, operating results and revolver availability should fund requirements for the foreseeable future.
- Supply of molybdenum-99 (Moly), used in TechneLite, remains a material risk. NTP’s latest processing outage began in April 2019, after quarter-end; the company reported that it could not meet all TechneLite demand on certain manufacturing days during outages. New ANSTO capacity was approved for the company’s use but was still ramping; SHINE supply was estimated to begin in 2021, subject to operational and regulatory approvals.
- DEFINITY’s composition-of-matter patent expires in June 2019, while a method-of-use patent runs to March 2037. The company reported no generic applicant notice as of the filing date but warned of potential generic competition. A modified formulation could be available in 2020 if approved; in-house manufacturing capability was expected by early 2021, neither timing assured.
- JHS is the sole-source manufacturer for DEFINITY and several other products. The company is pursuing supply-chain diversification and facility investment, but those efforts may not succeed on schedule. China DEFINITY approval was delayed by packaging-component and clinical-data issues.
- Clinical development and regulatory approval for DEFINITY’s LVEF indication, flurpiridaz F 18 and LMI 1195 involve substantial cost and uncertainty. Management noted ongoing Phase 3 work and regulatory dependencies; no approval or commercial outcome is assured.
- The company is pursuing monetary damages in arbitration with Pharmalucence over an unsuccessful DEFINITY manufacturing and supply arrangement; outcome and any recovery are uncertain. A $28.2 million surety bond provides required financial assurance for facility decommissioning; the recorded asset-retirement obligation was $11.9 million.
- Management identified competition, reimbursement, third-party manufacturing and customer dependence, regulatory compliance, indebtedness and product-development execution among the principal risks. It reported effective disclosure controls and no material changes in internal control during the quarter.
Investor verification points
- Track DEFINITY volume, pricing, rebate levels and the timing or impact of potential generic competition following the June 2019 patent expiration.
- Verify Moly supply continuity, the operational ramp of ANSTO’s new facility, and any resulting TechneLite sales or margin effects.
- Assess whether capital spending supports the planned North Billerica manufacturing capability and whether the project meets its stated timing.
- Monitor debt repayment and covenant headroom, especially given the large 2022 principal maturity and constrained revolver availability.
- Follow clinical-trial, regulatory and China-approval milestones, as well as the Pharmalucence arbitration; outcomes and financial effects remain uncertain.